Beware the cost-benefit analysis
11:19 EDT 25 Jul 2012 | British Medical Journal
bmj;345/jul25_2/e5040/FIG1F1fig1The drug industry champions chronic disease. This might be benevolence, but I suspect other motives. Consider the new anticoagulants for atrial fibrillation that do...
Original Article: Beware the cost-benefit analysis
More From BioPortfolio on "Beware the cost-benefit analysis"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
